A review of types 1 and 2 diabetes mellitus and their treatment with insulin

American Journal of Therapeutics

Volumn 13, Issue 4, 2006, Pages 349-361

  Salsali, Afshin ^a   Nathan, Muriel ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Diabetes; Insulin analogs; Ketoacidosis; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANABOLIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOFIBRATE; CORTICOSTEROID; DILTIAZEM; FENFLURAMINE; GUANETHIDINE; HUMALOG PEN; HUMAN INSULIN; HUMULIN L; HUMULIN U; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LANTUS DETEMIR; METFORMIN; MONOAMINE OXIDASE INHIBITOR; NEUTRAL INSULIN; NICOTINIC ACID; NOVOLIN N PENFILLED; NOVOLIN R; NOVOLIN R PENFILLED; ORAL CONTRACEPTIVE AGENT; PENTAMIDINE; PROTAMINE; SALICYLIC ACID; SULFONYLUREA; TETRACYCLINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; ZINC;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRAIN DISEASE; BRAIN PERFUSION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LIPOATROPHY; LONG TERM CARE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URTICARIA; WEIGHT GAIN;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EMERGENCY MEDICAL SERVICES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 33749331276     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200607000-00012     Document Type: Review

References (43)

1. Centers for Disease Control and Prevention. General information and national estimates on diabetes in the United States. National Diabetes Fact Sheet, 2003.
2. World Health Organization. Diabetes, Action Now. 2004.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28 (Suppl 1):S37-S42.
4. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331:1428-1436.
5. Kahn SE. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058.
6. Hiroaki M, Eisenbarth GS. Genetics and environmental factors in endocrine/organ-specific autoimmunity: have there been any major advances? Springer Semin Immunopathol. 2002;24:231-242.
7. Imagawa A, Hanafusa T, Tamura S, et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes. 2001;50:1269-1273.
8. Kimpimaki T, Kulmala P, Savola K, et al. Disease-associated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk. J Clin Endocrinol Metab. 2000;85:1126-1132.
9. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care. 2001;24:1460-1467.
10. Colditz GA, Willett WC, Rotnitzky A. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122:481.
11. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts and different goals. Endocrinol Metab Clin North Am. 2004;33:283-303.
12. Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715-722.
13. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
14. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
15. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
16. Raskin P, Newton CA. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004;164:1925-1931.
17. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988-2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
18. Davis T, Edelman SV, et al. Insulin therapy in type 2 diabetes mellitus. Med Clin North Am. 2004;88:865-895.
19. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: effects on mortality at one year. J Am Coll Cardiol. 1995;26:57-65.
20. Chaudhuri A, Janicke D, Wilson MF, et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation. 2004;109:849-854.
21. Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12:141-146.
22. Rosenzweig JL. Principles of insulin therapy. In: Kahn CR, Weir GC, eds. Joslin's Diabetes. 13th ed. Malvern, PA: Lea & Febiger; 1994:460-484.
23. Gulan M, Gottesman IS, Zinman B, et al. Biosynthetic human insulin improves postprandial glucose excursions in type 1 diabetes. Ann Intern Med. 1987;107:506-509.
24. Richter B, Neises G, Bergerhoff K, et al. Human versus animal insulin in people with diabetes mellitus: a systematic review. Endocrinol Metab Clin North Am. 2002;31:723-749.
25. Hirsch IB. Drug therapy insulin analogues. N Engl J Med. 2005;352:174-183.
26. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Multicenter insulin lispro study group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46:265-270.
27. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin dependent diabetes mellitus. Arch Intern Med. 1997;157:1249-1255.
28. Heller SRk, Amiel SA, Mansell P, et al. Effects of fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care. 1999;22:1607-1611.
29. Kennedy FP. Insulin therapy. In: Leahy JL, Clark NG, Cefalu NG, eds. Medical Management of Diabetes Mellitus. New York: Marcel Dekker, Inc; 2000:285-308.
30. Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of Glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care. 2003;26:3080-3086.
31. Cryer PE. Hypoglycemia: the limiting factor in glycaemic management of type 1 and type 2 diabetes. Diabetologia. 2002;45:937-948.
32. Unger RH. Meticulous control of diabetes: benefits, risks and precautions. Diabetes. 1982;31:479-483.
33. Raskin P. The Somogyi phenomenon. Sacred cow or bull? Arch Intern Med. 1984;144:781-787.
34. Tordjman KM, Havlin CE, Levandoski LA, et al. Failure of nocturnal hypoglycemia to cause fasting hyperglycemia in patients with insulin dependent diabetes mellitus. N Engl J Med. 1987;317:1552-1559.
35. Kalambokis GN, Tsatsoulis AA, Tsianos EV, et al. The edematogenic properties of insulin. Am J Kidney Dis. 2004;44:575-590.
36. Kahn CR, Mann D, Rosenthal AS, et al. The immune response to insulin in man: interaction of the HLA alloantigens and the development of the immune response. Diabetes. 1982;31:716-723.
37. Reeves WG, Allen BR, Tattersall RB, et al. Insulin induced lipoatrophy evidence for an immune pathogenesis. BMJ. 1980;1:1500-1506.
38. Goldstein DE, Blinder KJ, Ide CH, et al. Glycemic control and development of retinopathy in youth-onset insulin dependent diabetes mellitus. Ophthalmology. 1993;100:1125-1132.
39. Cefalu WT. Evaluation of alternative strategies for optimizing glycemia: progress to date. Am J Med. 2002;113(Suppl 6A):23S-35S.
40. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001;24:131-153.
41. Nathan MH. Diabetic ketoacidosis and hyperosmolar coma. In: Leahy JL, Clark NG, Cefalu WT, eds. Medical Management of Diabetes Mellitus. New York: Marcel Dekker, Inc; 2000:655-686.
42. Waldhausl W, Kleinberger G, Korn A, et al. Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration. Diabetes. 1979;28:577-584.
43. Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004;117:291-296.